Lee, 39,153 patient various antiandrogen prophylaxis study: 21% lower severe cases [p=0.03] and 11% fewer cases [p=0.001] https://c19p.org/lee5
copied to clipboard
A population-level analysis of the protective effects of androgen deprivation therapy against COVID-19 disease incidence and severity
et al., Frontiers in Medicine, doi:10.3389/fmed.2022.774773
Retrospective 3,057 androgen deprivation therapy patients in the USA, and 36,096 control patients with cancer, showing lower risk of cases and severity with ADT.
|
risk of severe case, 21.4% lower, RR 0.79, p = 0.03, treatment 76 of 295 (25.8%), control 727 of 2,427 (30.0%), NNT 24, adjusted per study, odds ratio converted to relative risk, propensity score weighting, multivariable.
|
|
risk of case, 11.3% lower, RR 0.89, p < 0.001, treatment 295 of 3,057 (9.6%), control 2,427 of 36,096 (6.7%), adjusted per study, odds ratio converted to relative risk, propensity score weighting, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lee et al., 3/7/2022, retrospective, USA, North America, peer-reviewed, 14 authors, study period 15 February, 2020 - 15 July, 2020.
Contact:
rhauger@health.ucsd.edu, mrettig@mednet.ucla.edu.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.